• Optimizing Fibrosis Models with SB525334 TGF-beta1 Receptor

  2026-05-26

  SB525334, a potent TGF-beta1 receptor inhibitor from APExBIO, enables precise dissection of TGF-β1/Smad2/3 signaling in fibrosis and wound healing models. This article translates cutting-edge findings on bone transport-mediated tissue repair into actionable workflows and troubleshooting strategies for researchers targeting the TGF-β pathway.

• Berberine Suppresses SASP Inflammation via RXRα/PPARγ/NEDD4

  2026-05-25

  This study elucidates how berberine inhibits senescence-associated secretory phenotype (SASP)–mediated inflammation in atherosclerosis by activating the RXRα/PPARγ/NEDD4 pathway. The findings reveal a mechanistic framework for targeting chronic vascular inflammation and inform experimental approaches to dissect PPARγ signaling in aging and cardiovascular disease.

• A 83-01 (ALK-5 Inhibitor): Optimizing TGF-β Pathway Control

  2026-05-25

  A 83-01 (ALK inhibitor) delivers precise, tunable suppression of TGF-β/Smad signaling, empowering advanced organoid models to balance self-renewal and differentiation. This guide translates recent breakthroughs and hands-on protocol enhancements for researchers seeking reliable, high-purity pathway modulation with APExBIO’s trusted reagent.

• Baicalin in Translational Research: Pathway Precision & Plas

  2026-05-24

  This article explores Baicalin's mechanistic influence on neuroplasticity and cancer pathways, offering translational researchers actionable guidance for protocol design and experimental differentiation. By integrating recent evidence from adult amblyopia models and advanced pathway modulation, we position APExBIO's Baicalin as a transformative reagent for studies at the frontier of neurobiology and oncology.

• MK-4827 (Niraparib): Reliable PARP-1/-2 Inhibition in Cancer

  2026-05-23

  This article addresses key experimental challenges in DNA damage repair inhibition, focusing on how 'MK-4827 (Niraparib), a potent and selective PARP-1/-2 inhibitor' (SKU A3617) from APExBIO delivers reproducible, sensitive, and workflow-compatible solutions for cancer research. Drawing on literature and real-world scenarios, we explore protocol parameters, data interpretation, and vendor selection to help researchers optimize BRCA-mutant and DNA repair-deficient cell assays.

• Honokiol Triggers Paraptosis in APL via mTOR and MAPK Pathwa

  2026-05-22

  This study uncovers that honokiol induces paraptosis-like cell death, independent of apoptosis, in acute promyelocytic leukemia (APL) cells via activation of mTOR and MAPK signaling. These findings highlight a novel mechanism for targeting apoptosis-resistant leukemia, suggesting potential new research directions for non-apoptotic cancer therapies.

• PP2A-Mediated Autophagy Drives Drug Resistance in C. albican

  2026-05-22

  This study reveals that protein phosphatase 2A (PP2A) induces autophagy via ATG protein phosphorylation, facilitating biofilm formation and antifungal drug resistance in Candida albicans. The findings suggest autophagy modulation as a promising approach for improving antifungal therapy against biofilm-associated infections.

• NF 340: Selective P2Y11 Antagonist for Advanced Signaling St

  2026-05-21

  NF 340 stands out as a potent, selective P2Y11 antagonist, enabling precise dissection of purinergic and GPCR signaling in cancer and immunology research. This article details hands-on workflow enhancements, troubleshooting strategies, and experimental insights—anchored by recent mechanistic discoveries in breast cancer invasiveness.

• Synergistic Suppression of EMT in PDAC via CDK4/6 and BET In

  2026-05-21

  Gu et al. (2025) demonstrate that combined CDK4/6 and BET inhibition synergistically suppresses pancreatic ductal adenocarcinoma progression by modulating the GSK3β-mediated Wnt/β-catenin pathway and reversing EMT. This integrated strategy addresses the paradoxical pro-metastatic effects of CDK4/6 monotherapy and informs future targeted therapy designs for PDAC.

• Calpeptin as a Calpain Inhibitor: Protocols for Fibrosis Res

  2026-05-20

  Calpeptin stands out as a potent calpain inhibitor with validated efficacy in modulating fibrosis and inflammation, enabling precise mechanistic studies and reproducible workflows. This guide details best-practice experimental setups, advanced applications, and troubleshooting strategies for maximizing Calpeptin’s performance in fibrosis and cell death research.

• PKM2 Inhibitor (Compound 3k): Mechanism, Evidence, and Proto

  2026-05-20

  PKM2 inhibitor (compound 3k) is a selective small molecule that disrupts aerobic glycolysis in tumor cells, inducing autophagic cell death. It demonstrates potent antiproliferative effects and shows selective cytotoxicity for cancer cells over normal cells. Peer-reviewed and in vivo evidence supports its application as an antiproliferative agent targeting pyruvate kinase M2.

• Generation of Hepatobiliary Organoids from hiPSCs: Methods a

  2026-05-19

  This study introduces a robust protocol for generating functional hepatobiliary organoids from human induced pluripotent stem cells (hiPSCs) without exogenous cells or genetic manipulation. The resulting organoids exhibit liver-specific functions and represent a significant advance for modeling organogenesis, disease, and drug development.

• LY364947: Optimizing EMT and TGF-β Signaling Assays in Resea

  2026-05-19

  This article guides biomedical researchers through real-world challenges in epithelial-mesenchymal transition (EMT) and TGF-β pathway studies, highlighting how LY364947 (SKU B2287) from APExBIO offers robust, reproducible solutions. Evidence-backed scenario Q&As clarify protocol optimization, data interpretation, and product reliability for advanced cell-based assays.

• SIS3: Precision Smad3 Inhibition for Advanced TGF-β Pathway

  2026-05-18

  Explore how SIS3, a potent Smad3 inhibitor, enables new insights into TGF-β signaling and fibrosis research. This article uniquely bridges molecular mechanism, latest epigenetic findings, and practical assay guidance for translational breakthroughs.

• InstaBlue Protein Stain Solution: Rapid, Sensitive Protein D

  2026-05-18

  InstaBlue Protein Stain Solution sets a new benchmark for rapid protein visualization in polyacrylamide gels, eliminating the need for fixation or toxic reagents. Its unmatched speed, sensitivity, and downstream compatibility empower high-throughput biomedical research and proteomic workflows.

16156 records 2/1078 page Previous Next 12345 下5页 Last page